# Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

> **NCT07165847** · PHASE2 · RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Immunotherapy
- Gastric Cancer (GC)
- Radiotherapy
- Neoadjuvant Therapy
- Neoadjuvant Chemoimmunotherapy

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab
- **DRUG:** Oxaliplatin
- **DRUG:** Tegafur
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT07165847
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-23
- **Primary completion:** 2028-09-23
- **Final completion:** 2030-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07165847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07165847, "Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07165847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*